AKBA
Akebia Therapeutics, Inc.Company with tickers: AKBA
CIK
1517022
CUSIP
00972D105
Shares Outstanding
268,258,243
13F Activity (30d)
144 filings
140 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $53,544,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | $12,290,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Gross Profit | — | ||||
| Operating Expenses | $45,950,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $14,807,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-4,696,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-9,054,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.03 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.03 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |